Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials

Cancer

Volumn 98, Issue 2, 2003, Pages 229-238

  Robertson, John F R ^a   Osborne, C Kent ^b   Howell, Anthony ^c   Jones, Stephen E ^d,e   Mauriac, Louis ^f   Ellis, Matthew ^g   Kleeberg, Ulrich R ^h   Come, Steven E ⁱ   Vergote, Ignace ^j   Gertler, Stan ^k   Buzdar, Aman ^l   Webster, Alan ^m   Morris, Charles ^m  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^f INSTITUT BERGONIÉ   (France)

^g GEORGETOWN UNIVERSITY   (United States)

^h Haematologische/Oncologische Praxis   (Germany)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k OTTAWA REGIONAL CANCER CENTRE   (Canada)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m ASTRAZENECA   (United Kingdom)

more..

Author keywords

Combined analysis; Duration of response; Estrogen receptor antagonist; Fulvestrant

Indexed keywords

ANASTROZOLE; FULVESTRANT; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ARTICLE; ASTHENIA; BLEEDING; BREAST CARCINOMA; CANCER GROWTH; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEADACHE; HOT FLUSH; HUMAN; INCIDENCE; INFLAMMATION; INJECTION PAIN; INJECTION SITE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OSTEOARTHRITIS; PAIN; PARALLEL DESIGN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; TREATMENT OUTCOME; URINARY TRACT INFECTION; VAGINITIS; VASODILATATION; WEIGHT GAIN;

EID: 0038683988     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11468     Document Type: Article

References (22)

1. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two Phase III trials. J Clin Oncol. 1996;14:2000-2011.
2. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer. 1996;74:1286-1291.
3. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol. 1998;9:639-645.
4. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867-3873.
5. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000;7:17-28.
6. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5 (10)-triene-3,17betadiol (Faslodex™) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001;61:6739-6746.
7. DeFriend DJ, Anderson E, Bell J, et al. Effects of 4-hydroxytamoxifen and a novel pure antiestrogen (ICI 182,780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer. 1994;70:204-211.
8. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995;87:746-750.
9. DeFriend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Res. 1994;54:408-414.
10. Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antiestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet. 1995;345:29-30.
11. Howell A, DeFriend DJ, Robertson JF, et al. Pharmacokinetics, pharmacological, and anti-tumour effects of the specific anti-oestrogen ICI 182,780 in women with advanced breast cancer. Br J Cancer. 1996;74:300-308.
12. Robertson JF, Blamey RW, Howell A, Anderson L, DeFriend D, Walton P. Duration of response to ICI 182,780 appears significantly longer than "Megace" in tamoxifen-resistant breast cancer [abstract]. Breast Cancer Res Treat. 1996;37(Suppl):33.
13. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396-3403.
14. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386-3395.
15. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. A project of the Programme on Clinical Oncology of the International Union against Cancer, Geneva, Switzerland. Cancer. 1977;39:1289-1294.
16. Robertson JF. A comparison of the single-dose pharmacokinetics of ICI 182,780 ("Faslodex") 250 mg when given as either a one × 5-ml intra-muscular injection or two × 2.5-mL injections in postmenopausal women with advanced breast cancer [abstract]. Breast Cancer Res Treat. 2000;64:53.
17. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex™) development of a novel "pure" antiestrogen. Cancer. 2000;89:817-825.
18. Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics. 2001;19:1091-1102.
19. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16:453-461.
20. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000;18:1399-1411.
21. Donnellan PP, Douglas SL, Cameron DA, Leonard RC. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001;19:2767.
22. Goss PE, Winer EP, Tannock IF, Schwartz LH. Randomized Phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol. 1999;17:52-63.